GlaxoSmithKline Accelerates Review of Exelixis’ XL880

Exelixis, Inc. announced that it has agreed to a request from GlaxoSmithKline (GSK) to initiate its review of XL880 before the compound reaches proof-of-concept.
PR Newswire